AstraZeneca PLC / Rigel Pharmaceuticals, Inc. (Fostamatinib license)
2010 · Licensing/Option · $1.2B · Terminated
Announcement Sentiment
57
Neutral / mixed
AstraZeneca/Rigel exclusive worldwide license for fostamatinib: $100M upfront + up to $345M dev/reg/first-sale milestones + up to $800M sales milestones + tiered double-digit royalties. Includes Rigel's broader Syk inhibitor portfolio.